FOLH1 and prostate carcinoma: The recent phase 3 ProPSMA trial showed improved sensitivity, specificity, and accuracy of [68Ga]Ga-PSMA-11 for detecting metastatic disease compared to standard of care CT and bone scan imaging in men with high risk prostate cancer [47].